FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362534469> ?p ?o ?g. }

• W4362534469 endingPage "6275" @default.
• W4362534469 startingPage "6275" @default.
• W4362534469 abstract "Abstract EZH2(Enhancer of zeste homolog2) is a catalytic subunit of PRC2 (polycomb repressive complex 2) for chromatin remodeling through methyl transfer activity. Previous studies have reported correlation between EZH2 and cancer progression with overexpression and mutations in various cancers. EZH1, homolog of EZH2, also has been known to role in development and progression of cancers by complementarily replacing EZH2. In recent researches, EZH1/2 dual inhibition showed global epigenetic modification on histone methylation and acetylation. Also, cancers associated with change in epigenetic factors such as mutations in subunit of SWI/SNF responded on EZH1/2 dual inhibition. Therefore, EZH1/2 dual inhibition is expected to be an effective strategy for cancer treatment. Herein, we present a novel potent EZH1/2 dual inhibitor, DW91170, as a promising candidate for treatment of lymphoma with improved anti-cancer activity. DW91170 selectively inhibited EZH1 and EZH2 enzyme activity. DW91170 brought about histone modification by reducing tri-methylation and enhancing acetylation of H3K27, which increased expression of target genes and cell cycle arrest was confirmed by treatment of DW91170. DW91170 showed effective tumor growth inhibition in two types of EZH2 hot spot mutation models. In Pfeiffer (A677 mutation) and WSU-DLCL2 (Y641 mutation) CDX models, DW91170 showed improved tumor regression activity with no significant abnormal signs such as weight loss. In order to verify the potential of DW91170 in R/R-lymphoma patients, the anti-cancer effect was evaluated in Rituximab-resistant cell line and R/R-DLBCL patient-derived PDX model. As a result, DW91170 efficiently inhibited Rituximab-resistant cell proliferation and suppressed tumor growth in R/R-DLBCL PDX model more significantly compared to other EZH inhibitors. Moreover, DW91170 has a good absorption profile that works in a physiological condition. Taken together, we demonstrated that DW91170, a dual epigenetic regulator of EZH1 and EZH2, showed great anti-tumor activities in various lymphoma cell lines and animal models such as CDX and PDX. We are currently trying to expand indication into solid tumor to find a targetable population in clinical trials. Citation Format: Doc-Gyun Jeong, Woon Heo, DongHyuk Shin, Yeonkyung Oh, Sangho Lee, Seongsu Jeong, Whuijung Park, Jiyoung Woo, Chanseok Jeon, Subin Kim, Jaekyung Lim, Yun-Ha Hwang. DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6275." @default.
• W4362534469 created "2023-04-06" @default.
• W4362534469 creator A5007560219 @default.
• W4362534469 creator A5008666758 @default.
• W4362534469 creator A5011636038 @default.
• W4362534469 creator A5015735286 @default.
• W4362534469 creator A5023663615 @default.
• W4362534469 creator A5025851083 @default.
• W4362534469 creator A5027662394 @default.
• W4362534469 creator A5027759021 @default.
• W4362534469 creator A5034043684 @default.
• W4362534469 creator A5034528772 @default.
• W4362534469 creator A5039919556 @default.
• W4362534469 creator A5055352784 @default.
• W4362534469 date "2023-04-04" @default.
• W4362534469 modified "2023-09-23" @default.
• W4362534469 title "Abstract 6275: DW91170: A novel potent EZH1/2 dual inhibitor for lymphoma treatment" @default.
• W4362534469 doi "https://doi.org/10.1158/1538-7445.am2023-6275" @default.
• W4362534469 hasPublicationYear "2023" @default.
• W4362534469 type Work @default.
• W4362534469 citedByCount "0" @default.
• W4362534469 crossrefType "journal-article" @default.
• W4362534469 hasAuthorship W4362534469A5007560219 @default.
• W4362534469 hasAuthorship W4362534469A5008666758 @default.
• W4362534469 hasAuthorship W4362534469A5011636038 @default.
• W4362534469 hasAuthorship W4362534469A5015735286 @default.
• W4362534469 hasAuthorship W4362534469A5023663615 @default.
• W4362534469 hasAuthorship W4362534469A5025851083 @default.
• W4362534469 hasAuthorship W4362534469A5027662394 @default.
• W4362534469 hasAuthorship W4362534469A5027759021 @default.
• W4362534469 hasAuthorship W4362534469A5034043684 @default.
• W4362534469 hasAuthorship W4362534469A5034528772 @default.
• W4362534469 hasAuthorship W4362534469A5039919556 @default.
• W4362534469 hasAuthorship W4362534469A5055352784 @default.
• W4362534469 hasConcept C104317684 @default.
• W4362534469 hasConcept C119157956 @default.
• W4362534469 hasConcept C121608353 @default.
• W4362534469 hasConcept C150194340 @default.
• W4362534469 hasConcept C185592680 @default.
• W4362534469 hasConcept C190727270 @default.
• W4362534469 hasConcept C2776915012 @default.
• W4362534469 hasConcept C2780737395 @default.
• W4362534469 hasConcept C33288867 @default.
• W4362534469 hasConcept C41091548 @default.
• W4362534469 hasConcept C50171091 @default.
• W4362534469 hasConcept C502942594 @default.
• W4362534469 hasConcept C54355233 @default.
• W4362534469 hasConcept C64927066 @default.
• W4362534469 hasConcept C86803240 @default.
• W4362534469 hasConceptScore W4362534469C104317684 @default.
• W4362534469 hasConceptScore W4362534469C119157956 @default.
• W4362534469 hasConceptScore W4362534469C121608353 @default.
• W4362534469 hasConceptScore W4362534469C150194340 @default.
• W4362534469 hasConceptScore W4362534469C185592680 @default.
• W4362534469 hasConceptScore W4362534469C190727270 @default.
• W4362534469 hasConceptScore W4362534469C2776915012 @default.
• W4362534469 hasConceptScore W4362534469C2780737395 @default.
• W4362534469 hasConceptScore W4362534469C33288867 @default.
• W4362534469 hasConceptScore W4362534469C41091548 @default.
• W4362534469 hasConceptScore W4362534469C50171091 @default.
• W4362534469 hasConceptScore W4362534469C502942594 @default.
• W4362534469 hasConceptScore W4362534469C54355233 @default.
• W4362534469 hasConceptScore W4362534469C64927066 @default.
• W4362534469 hasConceptScore W4362534469C86803240 @default.
• W4362534469 hasIssue "7_Supplement" @default.
• W4362534469 hasLocation W43625344691 @default.
• W4362534469 hasOpenAccess W4362534469 @default.
• W4362534469 hasPrimaryLocation W43625344691 @default.
• W4362534469 hasRelatedWork W2013220243 @default.
• W4362534469 hasRelatedWork W2327870959 @default.
• W4362534469 hasRelatedWork W2372830782 @default.
• W4362534469 hasRelatedWork W2375008293 @default.
• W4362534469 hasRelatedWork W2378413928 @default.
• W4362534469 hasRelatedWork W2427007523 @default.
• W4362534469 hasRelatedWork W2987470378 @default.
• W4362534469 hasRelatedWork W3012633978 @default.
• W4362534469 hasRelatedWork W3205814058 @default.
• W4362534469 hasRelatedWork W4367173850 @default.
• W4362534469 hasVolume "83" @default.
• W4362534469 isParatext "false" @default.
• W4362534469 isRetracted "false" @default.
• W4362534469 workType "article" @default.